Trials / Completed
CompletedNCT06310590
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
Study on the Safety and Effectiveness of NRT6003 Injection in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chengdu New Radiomedicine Technology Co. LTD. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.
Detailed description
The efficacy and safety of TareSphere in patients with unresectable HCC remains unknown. This trial is a prospective, multicenter, open-label, single-arm phase I trial designed to evaluate the safety and efficacy of NRT6003 injection. The primary objective is to evaluate the safety of NRT6003 Injection. While the secondary objectives include the assessments of the antitumoral efficacy, the improvement of patients´ quality of life, and the distribution characteristics of Yttrium-90 in body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NRT6003 Injection | Selective internal radiation therapy (SIRT) with TareSphere |
Timeline
- Start date
- 2023-08-08
- Primary completion
- 2025-06-10
- Completion
- 2025-06-10
- First posted
- 2024-03-15
- Last updated
- 2026-02-03
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06310590. Inclusion in this directory is not an endorsement.